FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897631607> ?p ?o ?g. }

• W2897631607 endingPage "viii662" @default.
• W2897631607 startingPage "viii662" @default.
• W2897631607 abstract "Background: The purpose of this study is to estimate 5-year survival rates for patients with early onset breast cancer, with and without a BRCA1/2, CHEK2, NOD2 mutation or TP53 polymorphisms and to identify prognostic factors among mutation carriers in breast cancer patients. Methods: In a study conducted in the years 2007-2016 in the Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch (COI) were analyzed prognostic factors and survival in 622 breast cancer including 60 BRCA mutation carriers, 46 CHEK2 mutation carriers, 29 NOD2 mutation carriers and 87 patients with TP53 polymorphisms. Control group was selected from breast cancer patients without mutation and polymorphisms (n = 400). Results: The five–year rate of OS was 75.9% for pts with BRCA mutation, 94.4% for CHEK2 mutation carriers, 96.6% for NOD2 mutation carriers and 100% for patients with TP53 polymorphisms. BRCA mutation carriers had insignificantly worse survival as compared to control group (p = 0.180). Patients with CHEK2 mutation had significantly better OS than control group (p = 0.032). Similarly NOD2 mutation carriers had also significantly better OS than control group (p = 0.043). Patients with TP53 polymorphisms carriers had higher OS in comparison to control group (p = 0.002). In subgroup of pts with N0 (Without lymph node metastases) BRCA mutation carriers was characterized by the worst OS (81.1%) among carriers of other mutations: CHEK2 (94.7%, P = 0.021), NOD2 (95.3%, p = 0.092) and TP53 polymorphisms (100%, p = 0.007) or control group (94.4%, p = 0.022). Similar tendency was observed according to N+ subgroup and subgroup with tumor size T1-T2. Higher tumor size (HR = 2.85), lymph node metastases (HR = 2.93) and HER2 overexpression (HR = 1.49) were significant factors for worse OS. Positive ER status was associated with a better OS (HR = 0.52, p = 0.001). Age <40 years (HR = 0.71, p = 0.255) was insignificantly favorable factor. Conclusions: CHEK2, NOD2 mutation carriers and patients with TP53 polymorphisms had better 5-year survival in comparison to patients with BRCA mutation and control group. Higher tumor size (T) and lymph node metastases (N+) were negative prognostic factors independently from the presence of mutations and polymorphisms. Legal entity responsible for the study: Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest." @default.
• W2897631607 created "2018-10-26" @default.
• W2897631607 creator A5016432105 @default.
• W2897631607 creator A5053139858 @default.
• W2897631607 date "2018-10-01" @default.
• W2897631607 modified "2023-09-30" @default.
• W2897631607 title "Survival from breast cancer in patients with BRCA1/2, CHEK2, NOD2 mutations and TP53 (c.[215G>C]) polymorphisms" @default.
• W2897631607 doi "https://doi.org/10.1093/annonc/mdy303.041" @default.
• W2897631607 hasPublicationYear "2018" @default.
• W2897631607 type Work @default.
• W2897631607 sameAs 2897631607 @default.
• W2897631607 citedByCount "0" @default.
• W2897631607 crossrefType "journal-article" @default.
• W2897631607 hasAuthorship W2897631607A5016432105 @default.
• W2897631607 hasAuthorship W2897631607A5053139858 @default.
• W2897631607 hasBestOaLocation W28976316071 @default.
• W2897631607 hasConcept C104317684 @default.
• W2897631607 hasConcept C121608353 @default.
• W2897631607 hasConcept C126322002 @default.
• W2897631607 hasConcept C13514818 @default.
• W2897631607 hasConcept C143998085 @default.
• W2897631607 hasConcept C2776071976 @default.
• W2897631607 hasConcept C2780194787 @default.
• W2897631607 hasConcept C501734568 @default.
• W2897631607 hasConcept C530470458 @default.
• W2897631607 hasConcept C54355233 @default.
• W2897631607 hasConcept C71924100 @default.
• W2897631607 hasConcept C86803240 @default.
• W2897631607 hasConceptScore W2897631607C104317684 @default.
• W2897631607 hasConceptScore W2897631607C121608353 @default.
• W2897631607 hasConceptScore W2897631607C126322002 @default.
• W2897631607 hasConceptScore W2897631607C13514818 @default.
• W2897631607 hasConceptScore W2897631607C143998085 @default.
• W2897631607 hasConceptScore W2897631607C2776071976 @default.
• W2897631607 hasConceptScore W2897631607C2780194787 @default.
• W2897631607 hasConceptScore W2897631607C501734568 @default.
• W2897631607 hasConceptScore W2897631607C530470458 @default.
• W2897631607 hasConceptScore W2897631607C54355233 @default.
• W2897631607 hasConceptScore W2897631607C71924100 @default.
• W2897631607 hasConceptScore W2897631607C86803240 @default.
• W2897631607 hasLocation W28976316071 @default.
• W2897631607 hasOpenAccess W2897631607 @default.
• W2897631607 hasPrimaryLocation W28976316071 @default.
• W2897631607 hasRelatedWork W1945350395 @default.
• W2897631607 hasRelatedWork W2023425329 @default.
• W2897631607 hasRelatedWork W2032876191 @default.
• W2897631607 hasRelatedWork W2035701062 @default.
• W2897631607 hasRelatedWork W2341539240 @default.
• W2897631607 hasRelatedWork W2402528160 @default.
• W2897631607 hasRelatedWork W2412994804 @default.
• W2897631607 hasRelatedWork W2628566517 @default.
• W2897631607 hasRelatedWork W3037426265 @default.
• W2897631607 hasRelatedWork W3216318789 @default.
• W2897631607 hasVolume "29" @default.
• W2897631607 isParatext "false" @default.
• W2897631607 isRetracted "false" @default.
• W2897631607 magId "2897631607" @default.
• W2897631607 workType "article" @default.